Dexcom Inc Stock Performance
| DXCM Stock | USD 73.04 0.96 1.30% |
On a scale of 0 to 100, DexCom holds a performance score of 13. The firm shows a Beta (market volatility) of 0.71, which means possible diversification benefits within a given portfolio. As returns on the market increase, DexCom's returns are expected to increase less than the market. However, during the bear market, the loss of holding DexCom is expected to be smaller as well. Please check DexCom's skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether DexCom's price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in DexCom Inc are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental indicators, DexCom displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.30) | Five Day Return 0.12 | Year To Date Return 9.77 | Ten Year Return 305.55 | All Time Return 2.4 K |
Last Split Factor 4:1 | Last Split Date 2022-06-13 |
1 | DXCM Deadline DXCM Investors with Losses in Excess of 100K Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit | 12/15/2025 |
2 | DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - DXCM | 12/22/2025 |
3 | Acquisition by Kevin Sayer of 85490 shares of DexCom subject to Rule 16b-3 | 01/13/2026 |
4 | Is DexCom Pricing Justified After Recent Multi Year Share Price Weakness | 01/14/2026 |
5 | Will Strong 2025 Revenue And 2026 Outlook Shift DexComs Long-Term Growth Narrative | 01/15/2026 |
6 | 1 Growth Stock Down 19 percent to Buy Right Now | 01/21/2026 |
7 | INVESTOR NOTICE Kaskela Law Firm Announces Stockholder Investigation of DexCom, Inc. and Encourages Long-Term Investors to Contact the Firm | 01/27/2026 |
8 | Is Dexcom Pricing Reflect Long Term Potential After Continuous Glucose Monitoring Focus | 01/28/2026 |
9 | Q4 Preliminary Figures and 2026 Guidance Make DexCom Look Attractive | 01/30/2026 |
| Begin Period Cash Flow | 567.5 M | |
| Total Cashflows From Investing Activities | -207.5 M |
DexCom Relative Risk vs. Return Landscape
If you would invest 6,043 in DexCom Inc on November 2, 2025 and sell it today you would earn a total of 1,261 from holding DexCom Inc or generate 20.87% return on investment over 90 days. DexCom Inc is currently generating 0.3245% in daily expected returns and assumes 1.9388% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than DexCom, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
DexCom Target Price Odds to finish over Current Price
The tendency of DexCom Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 73.04 | 90 days | 73.04 | about 7.12 |
Based on a normal probability distribution, the odds of DexCom to move above the current price in 90 days from now is about 7.12 (This DexCom Inc probability density function shows the probability of DexCom Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days DexCom has a beta of 0.71 suggesting as returns on the market go up, DexCom average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding DexCom Inc will be expected to be much smaller as well. Additionally DexCom Inc has an alpha of 0.0532, implying that it can generate a 0.0532 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). DexCom Price Density |
| Price |
Predictive Modules for DexCom
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as DexCom Inc. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of DexCom's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
DexCom Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. DexCom is not an exception. The market had few large corrections towards the DexCom's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold DexCom Inc, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of DexCom within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.05 | |
β | Beta against Dow Jones | 0.71 | |
σ | Overall volatility | 4.95 | |
Ir | Information ratio | 0.02 |
DexCom Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of DexCom for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for DexCom Inc can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| DexCom Inc is unlikely to experience financial distress in the next 2 years | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Q4 Preliminary Figures and 2026 Guidance Make DexCom Look Attractive |
DexCom Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of DexCom Stock often depends not only on the future outlook of the current and potential DexCom's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. DexCom's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 412.7 M | |
| Cash And Short Term Investments | 2.6 B |
DexCom Fundamentals Growth
DexCom Stock prices reflect investors' perceptions of the future prospects and financial health of DexCom, and DexCom fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DexCom Stock performance.
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.0702 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 28.11 B | ||||
| Shares Outstanding | 390.02 M | ||||
| Price To Earning | 245.31 X | ||||
| Price To Book | 10.59 X | ||||
| Price To Sales | 6.34 X | ||||
| Revenue | 4.03 B | ||||
| Gross Profit | 2.66 B | ||||
| EBITDA | 945.7 M | ||||
| Net Income | 576.2 M | ||||
| Cash And Equivalents | 2.37 B | ||||
| Cash Per Share | 6.14 X | ||||
| Total Debt | 2.59 B | ||||
| Debt To Equity | 1.17 % | ||||
| Current Ratio | 3.77 X | ||||
| Book Value Per Share | 6.99 X | ||||
| Cash Flow From Operations | 989.5 M | ||||
| Earnings Per Share | 1.80 X | ||||
| Market Capitalization | 28.64 B | ||||
| Total Asset | 6.48 B | ||||
| Retained Earnings | 1.6 B | ||||
| Working Capital | 1.37 B | ||||
| Current Asset | 231.3 M | ||||
| Current Liabilities | 66.9 M | ||||
About DexCom Performance
By examining DexCom's fundamental ratios, stakeholders can obtain critical insights into DexCom's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that DexCom is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 111.77 | 68.37 | |
| Return On Tangible Assets | 0.08 | 0.09 | |
| Return On Capital Employed | 0.15 | 0.16 | |
| Return On Assets | 0.08 | 0.08 | |
| Return On Equity | 0.25 | 0.26 |
Things to note about DexCom Inc performance evaluation
Checking the ongoing alerts about DexCom for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DexCom Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DexCom Inc is unlikely to experience financial distress in the next 2 years | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Q4 Preliminary Figures and 2026 Guidance Make DexCom Look Attractive |
- Analyzing DexCom's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DexCom's stock is overvalued or undervalued compared to its peers.
- Examining DexCom's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DexCom's management team can have a significant impact on its success or failure. Reviewing the track record and experience of DexCom's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DexCom's stock. These opinions can provide insight into DexCom's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Will Health Care Equipment & Supplies sector continue expanding? Could DexCom diversify its offerings? Factors like these will boost the valuation of DexCom. Projected growth potential of DexCom fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DexCom data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.099 | Earnings Share 1.8 | Revenue Per Share | Quarterly Revenue Growth 0.216 | Return On Assets |
Understanding DexCom Inc requires distinguishing between market price and book value, where the latter reflects DexCom's accounting equity. The concept of intrinsic value—what DexCom's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push DexCom's price substantially above or below its fundamental value.
It's important to distinguish between DexCom's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DexCom should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, DexCom's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.